Hawaii Biotech Inc reports favourable phase 1 interim results to treat West Nile Virus
The results demonstrated a favourable safety profile in 24 subjects across four cohorts. The Phase 1 study was designed as an ascending dose study to assess the safety of Hawaii Biotech’s West Nile Virus vaccine among healthy adult volunteers who had not been exposed to the West Nile or similar virus. The study also examined antibody development to the vaccine. The overall profile was favourable with no serious adverse events. Based on these results, Hawaii Biotech is preparing to proceed with additional safety studies in adults, as well as ultimately expanding studies into elderly, juvenile and immune-compromised populations.
“We are extremely pleased with the safety results of our West Nile Virus vaccine Phase 1 study and are encouraged by the presence of neutralizing antibodies in all individuals receiving the formulated vaccine,” notes Chief Executive Officer and President Dr. Elliot Parks. “Additionally, these results demonstrate the robustness of our protein production platform for the development of additional sub-unit vaccines in our product pipeline,” Parks states.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous